+------------------------------------------------------------------------------+
Actavis Seen Merging With Teva, Mylan or Novartis: Cowen 2014-01-10 14:57:50.988 GMT
By Catherine Larkin Jan. 10 (Bloomberg) -- Actavis ultimately will combine with Teva, Mylan or Novartis as generic-drug industry faces significant consolidation of suppliers, Cowen analyst Ken Cacciatore says in note. * Says ACT will continue to consolidate complementary businesses and create value in the interim “to better dictate terms upon their own exit” * Sees Meda, Salix, Galderma as acquisition candidates for ACT * Upgrades ACT to outperform from market perform, PT raised to $215 from $130 (vs Bloomberg avg $186) * NOTE: Earlier, Valeant Seen With ‘Most Urgency’ in Specialty Pharma M&A: Susquehanna * NOTE: From Jan. 8, Morgan Stanley Says Specialty Pharma Consolidation Will Continue
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Catherine Larkin in Chicago at +1-312-443-5968 or clarkin4@bloomberg.net
To contact the editor responsible for this story: Joanna Ossinger at +1-212-617-7789 or jossinger@bloomberg.net